Perfuse Therapeutics Acquired by Bayer | Healthcare M&A Deal

Bayer has acquired Perfuse Therapeutics, a ophthalmology business in California, for $2.45 billion. Perfuse Therapeutics develops intravitreal implant therapies for glaucoma and diabetic retinopathy, aiming to block a protein pathway that constricts blood vessels and drives ocular damage. Bayer acquires Perfuse Therapeutics to expand its eye drug pipeline and differentiate treatment options beyond standard drops and injections, with the lead program PER-001 in mid-stage testing. The strategic acquisition is structured with $300 million upfront and additional milestone-based payments tied to development, regulatory, and commercial benchmarks, subject to stockholder approval and antitrust clearance.